Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end-stage renal disease

Endocrine Practice

Volumn 14, Issue 8, 2008, Pages 961-966

  Pitoia, Fabián ^a   Ilera, Veronica ^b   Zanchetta, Maria B ^a   Foffano, Adriana ^a   Niepomniszcze, Hugo ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CASE REPORT; DIARRHEA; FEMALE; HEMODIALYSIS; HORMONAL THERAPY; HUMAN; KIDNEY FAILURE; MALE; SIDE EFFECT; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; THYROTROPIN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; MIDDLE AGED; THYROID TUMOR;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 65849355232     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.8.961     Document Type: Article

References (37)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
2. Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients. Clin Endocrinol (Oxf). 2002;57:523-527.
3. Golger A, Fridman TR, Eski S, Witterick IJ, Freeman JL, Walfish PG. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest. 2003;26:1023-1031.
4. Kuijt WJ, Huang SA. Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. J Clin Endocrinol Metab. 2005;90:6123-6125.
5. Dow KH, Ferrel BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613-619.
6. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006;91:878-884.
7. Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15:1147-1155.
8. Cohen O, Dabhi S, Karasik A, Zila Zwas S. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH [erratum in Eur J Endocrinol. 2005;153:627]. Eur J Endocrinol. 2004;150:285-290.
9. Wondisford FE, Radovick S, Moates JM, Usala SJ, Weintraub BD. Isolation and characterization of the human thyrotropin beta-subunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem. 1988;263:12538-12542.
10. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology. 1991;128:341-348.
11. Huber GK, Fong P, Concepcion ES, Davies TF, et al. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab. 1991;72:1328-1331.
12. Ramirez L, Braverman LE, White B, Emerson CH, et al. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab. 1997;82:2836-2839.
13. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab. 2001; 86:1660-1664.
14. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12:49-64.
15. Pitoia F, Tamer EE, Schere DB, Passerieu M, Bruno OD, Niepomniszcze H. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma. Medicina (B Aires). 2006;66:125-130.
16. Robbins RJ, Driedger A, Magner J, U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16:1121-1130.
17. Jawa A, Pendergrass M. A case of recombinant TSH for the treatment of papillary thyroid cancer in a patient with end stage renal disease. Abstract presented at: 75th Annual Meeting of the Thyroid Association; September 2003; Palm Beach, Florida.
18. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid. 2001;11:1025-1030.
19. Pitoia F, El Tamer E, Zanchetta MB, Danilowicz K, Lucas S, Niepomniszcze H. Niveles séricos de TSH luego de la administración de TSH recombinante en un paciente con carcinoma diferenciado de tiroides e insuficiencia renal terminal [article in Spanish]. Rev Arg Endocrinol Metab. 2006;43:83-89.
20. Lim VS. Thyroid function in patients with chronic renal failure. Am J Kidney Dis. 2001;38:S80-84.
21. Kaptein EM, Quion-Verde H, Chooljian CJ, et al. The thyroid in end-stage renal disease. Medicine (Baltimore). 1988;67:187-197.
22. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996;17:45-63.
23. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved -editorial. Am J Nephrol. 1998;18:89-95.
24. Sinsakul M, Ali A. Radioactive 131I use in end-stage renal disease: nightmare or nuisance? Semin Dial. 2004;17:53-56.
25. Wang TH, Lee CH, Tseng LM, Liu RH. The management of well-differentiated thyroid cancer with end-stage renal disease. Endocrine. 2003;21:227-231.
26. Seehofer D, Rayes N, Klupp J, et al. Prevalence of thyroid nodules and carcinomas in patients operated on for renal hyperparathyroidism: experience with 339 consecutive patients and review of the literature. World J Surg. 2005;29:1180-1184.
27. Demirer AN, Kemal Y, Gursoy A, Sahin M, Tutuncu NB. Clinicopathological characteristics of thyroid cancer in patients on dialysis for end-stage renal disease. Thyroid. 2008;18:45-50.
28. Pond F, Serpell JW, Webster A. Thyroid cancer in the renal transplant population: epidemiological study. ANZ J Surg. 2005;75:106-109.
29. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15:1321-1331.
30. Morrish DW, Filipow LJ, McEwan AJ, et al. 131I treatment of thyroid papillary carcinoma in a patient with renal failure. Cancer. 1990;66:2509-2513.
31. Magné N, Magné J, Bracco J, Bussière F. Disposition of radioiodine (131)I therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a case report. Jpn J Clin Oncol. 2002;32:202-205.
32. Howard N, Glasser M. Iodine 131 ablation therapy for a patient on maintenance haemodialysis. Br J Radiol. 1981; 54:259.
33. Daumerie C, Vynckier S, Caussin J, et al. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid. 1996;6:301-304.
34. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
35. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled Study. J Clin Endocrinol Metab. 2006;91:926-932.
36. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90: 5047-5057.
37. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab. 1994;78:188-196.